We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Adocia SAS Announces the Communication of its Clinical Results at Three Major Conferences

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Adocia SAS Announces the Communication of its Clinical Results at Three Major Conferences"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Adocia SAS, has announced that it has been invited to present the clinical results of its two leading BioChaperone products at three different conferences.

Adocia’s BioChaperone® is a library of polysaccharides modified with naturally occurring molecules. These polymers are designed to form a reversible molecular complex with therapeutic proteins in order to solubilize and stabilize these proteins and to control their delivery.

“Adocia has exciting opportunities to present to the scientific and medical communities the results obtained with the combination of BioChaperone and therapeutic proteins, and the potential of this system for protein formulation in general,” said Dr Gérard Soula, Adocia’s president and CEO.

Two BioChaperone products have proven their safety and efficacy in clinical trials.

The first is a new treatment for diabetic foot ulcers and consists of a combination of BioChaperone and Platelet Derived Growth Factor, rhPDGF-BB. BioChaperone PDGF-BB is currently being evaluated against Regranex® (beclapermin gel, Systagenix) in a large phase II clinical trial in India.

The study objective is to demonstrate the non-inferiority of BioChaperone PDGF-BB, applied once every two days, versus Regranex applied every day on percentage of complete wound closure after 20 weeks.

Interim analysis demonstrates the non-inferiority of BioChaperone PDGF-BB compared to Regranex even at a dose three times lower.

The second is an innovative fast-acting human insulin product for the postprandial glycemic control of diabetics. BioChaperone human insulin has been evaluated in a phase I clinical trial against a commercial fast-acting analog, NovoLog® (Novo Nordisk) and a regular human insulin, Actrapid® (Novo Nordisk) on 12 healthy volunteers in Germany.

The results of this study demonstrate that BioChaperone human insulin acts as fast as NovoLog® in the regulation of glycemia. These results have been disclosed in a previous press release (15th March 2011).

Other promising results on the formulation of monoclonal antibodies with BioChaperone will be presented during these conferences.

2nd Annual Protein Formulation Development Forum
June 15 – 17, 2011
Location: Hotel Avenida Palace - Barcelona, Spain

71st Scientific Sessions of the American Diabetes Association (2011)
June 24 – 28, 2011
Location: San Diego Convention Center - San Diego, California

38th Annual Meeting & Exposition of the Controlled Release Society
July 30, 2011
Location: Gaylord National Hotel and Convention Center - National Harbor, Maryland, U.S.A.

“The present results illustrate the large potential and versatility of BioChaperone to improve the efficacy of three different classes of proteins from small size proteins such as insulin, middle size proteins such as PDGF-BB, to large size proteins such as monoclonal antibodies,” said Dr Olivier Soula, Adocia’s vice-president and R&D director.